luminal b breast cancer ki67

Release time ：Dec-24,2024

Luminal B breast cancer is a subtype classified based on specific molecular markers present on the surface of tumor cells. Ki67, a protein associated with cell proliferation, reflects the proliferative activity of tumor cells. Typically, in Luminal B breast cancer, a high Ki67 index indicates active tumor cell proliferation, which correlates with increased tumor aggressiveness and a poorer prognosis.

The Ki67 index is categorized into low (<14%), intermediate (14%-20%), and high (>20%) levels. Patients with Luminal B breast cancer and a high Ki67 index often necessitate more aggressive therapeutic approaches, including chemotherapy, radiotherapy, and endocrine therapy. Moreover, the Ki67 index is a crucial biomarker for evaluating treatment efficacy and predicting the risk of recurrence.

For Luminal B breast cancer patients, knowing their Ki67 index is essential. It aids in a better understanding of their condition and assists physicians in devising personalized treatment strategies. It is advised that patients, under medical supervision, regularly monitor their Ki67 index and adjust treatment plans based on these results. Additionally, maintaining healthy lifestyle habits, such as a balanced diet and regular exercise, can enhance treatment outcomes and overall quality of life.